Quarterly report [Sections 13 or 15(d)]

BUSINESS COMBINATION (Details Narrative)

v3.26.3
BUSINESS COMBINATION (Details Narrative) - USD ($)
9 Months Ended
Mar. 04, 2025
Sep. 30, 2026
Jul. 06, 2026
Feb. 15, 2026
Dec. 31, 2025
Jul. 29, 2025
BUSINESS COMBINATION            
Sellers retention description amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of LUCEMYRA® and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of LUCEMYRA          
Common stock shares issued for acquisition 500,000 500,000        
Closing market price   $ 0.31        
Common stock price per share $ 0.31 $ 0.001 $ 0.36 $ 0.34 $ 0.001  
Common stock purchased 500,000          
Exercise price $ 1.00         $ 0.35
Fair value of stock issued $ 153,500          
Royalty payments   $ 108,260        
Upfront purchase price $ 400,000 $ 392,441        
Discounted at the risk-free rate   4.04%        
Discounted at required metric risk premium   24.09%